SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: A.J. Mullen who wrote (52144)8/5/2025 12:27:10 PM
From: A.J. Mullen1 Recommendation

Recommended By
OldAIMGuy

  Respond to of 52153
 
I was in too much of a hurry. Vertex has cancelled their follow-on to Journavx, which is already approved for acute pain, However, they got bad news from the FDA this morning regarding broadening the label for Journavx, fiercepharma.com “at this time, the FDA does not see a path to a broad indication,” Kewalramani (CEO of Vertex) said.